慢性阻塞性肺疾病新星-罗氟司特

Our country is gradually entering an aging society, and the threat COPD poses to residents' good quality of life cannot be ignored. COPD is a common respiratory disease that is progressive and involves chronic inflammation and parenchymal destruction leading to airflow limitation. In addition to lesions in the airways and lung tissue, advanced COPD can cause complications in other systems. The second-generation PDE4 selective inhibitor, for example, is the first PDE4 inhibitor approved for marketing by the US Food and Drug Administration. It can selectively inhibit PDE4 at low concentration levels. Roflumilast can effectively reduce lung inflammation, resist oxidative stress, enhance mucosal clearance and airway remodeling. Roflumilast reduces the degree of hyperinflation by increasing forced expiratory volume in one second (FEV 1) and forced vital capacity (FVC), thereby alleviating dyspnea. Currently, roflumilast is the new star in the treatment of COPD.

Roflumilast can inhibit the decomposition of cyclic nucleotide (cAMP) and promote its accumulation in cells, thereby activating protein kinase A and regulating immune and inflammatory responses. Roflumilast can reduce the activity of airway inflammatory cells, inhibit the production of pro-inflammatory factors, and block the transmission of pro-inflammatory response information. Roflumilast can inhibit the expression of intracellular adhesion molecules and CD11b, inhibit the release of TNF-α and chemokines by lung macrophages, and reduce local inflammatory reactions. Roflumilast can affect the expression of TGF-β1, fibronectin, connective tissue growth factor collagen level 1 IL-6 and other substances in airway smooth muscle cells, inhibiting airway remodeling. Roflumilast can inhibit excessive airway mucus secretion, reduce airway mucus protein levels, and promote ciliary swinging.

Common symptoms reported in the experiment were insomnia, nausea, diarrhea, weight loss, back pain, flu, headache, dizziness and loss of appetite.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.